News

Sponsors Are Guaranteed to Receive Precise, Conclusive Thorough QT Results or Pay Nothing

The use and number of cognitive-enhancing drugs is likely to grow substantially in the coming years, and researchers must prioritize the potential advantages and dangers of their use in healthy subjects, according to U.K. neuroscientists writing in The Lancet Psychiatry journal.

TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service.

Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.

Triumph Research Intelligence (TRI), based in London, UK and Raleigh, NC announces its Risk-Based Monitoring platform, Operational Platform for Review, Reporting and Analysis OPRA, for a combination of statistical calculations, data visualizations and operational activity management.

The emergence of risk-based monitoring (RbM) is creating a revolution in the way biopharmaceutical sponsors and CROs manage clinical trial quality.

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies.

Evaluating the use of new tumor measurement tools for studies of molecular-targeted cancer therapies.

The need for robust and standardized psychiatric outcomes measures in oncology trials has grown immensely

Faster go/no-go decisions is the primary driver of adaptive-design adoption by sponsors.

Initiative designed to boost understanding of medical device development in Europe.

Patient focused drug development is playing a larger role in study design and outcome measurement.

New ASCO study evaluating the cancer care system reveals mixed findings.

Outlining the requirements and benefits of FDA's four expedited drug approval pathways.

Following four key study-design steps is crucial to the delivery of a successful cross-border cancer study

Trial Design: Breaking Blood Cancer Barriers Adaptive Solutions in Oncology Clinical Technology: Tumor Imaging Ascension Sites: Enrollment Forecast Data Also in this issue: Innovation Initiative Debate in Europe R&D Investment: Public vs. Private The Psychology of Cancer

In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.

The European Medicines Agency (EMA), along with the Heads of Medicines Agencies (HMA), have published the ‘EU Medicines Agencies Network Strategy to 2020.

PAREXEL introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0

Biorasi, a full-service CRO, announced a strategic partnership with Medidata, where it has deployed Medidata's electronic data capture (EDC), management and reporting system, Medidata Rave®, to support Biorasi's Phase I through IV global clinical trial business.